Marksans Pharma zooms on getting USFDA’s approval for Cetirizine Hydrochloride Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Marksans Pharma is currently trading at Rs. 63.95, up by 2.30 points or 3.73% from its previous closing of Rs. 61.65 on the BSE.
The scrip opened at Rs. 61.50 and has touched a high and low of Rs. 64.50 and Rs. 61.45 respectively. So far 438713 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 97.50 on 14-Jun-2021 and a 52 week low of Rs. 49.20 on 26-Mar-2021.
Last one week high and low of the scrip stood at Rs. 64.50 and Rs. 59.40 respectively. The current market cap of the company is Rs. 2554.12 crore.
The promoters holding in the company stood at 48.25%, while Institutions and Non-Institutions held 3.17% and 48.58% respectively.
Marksans Pharma has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine Hydrochloride Tablets 5 mg and 10mg. It is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose. The product will be marketed under store brand labels and is comparable to the brand Zyrtec.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
